Instituut voor Neuropathische Pijn

ADL-5859 is a delta agonist for the opiod receptor family, and it might be of use for the treatment of neuropathic pain, by inducing less side effects as the current opioids. The compound is developed by Adolor Corporation (this is alsoi the Originator) and the compound is in phase II.

The delta agonists might also modulate other biological processes related to overactive bladder and depression.

From the Centre for the study and treatment of Neuropathic Pain and Neuropathy in Soest, the Netherlands

This site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof.

In our centre we are specialised in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.

April 2010, Jan M. Keppel Hesselink, MD, PhD